TempraMed Technologies - Public Comps and Valuation Multiples

TempraMed Technologies Overview

About TempraMed Technologies

TempraMed Technologies Ltd develops patent-protected solutions for managing and protecting temperature-sensitive medications. Its product range includes VIVI Cap for insulin pens and VIVI Epi for epinephrine injectors, which are distributed through pharmacy and retail networks globally. TempraMed generates the majority of its revenue from the sales of these devices, serving patients, healthcare providers, and pharmacy systems through operations in Southeast Asia, Europe, and Central America. The company enhances its reach by forming partnerships in the healthcare sector to broaden its access and drive usage in various geographic markets.

Founded

2023

HQ

Employees

Website

tempramed.com

Sectors

Medical Devices

Financials

Last FY Revenue $1.6M

Last FY EBITDA -$13.1M

EV

$38.9M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

TempraMed Technologies Financials

See TempraMed Technologies valuation multiples based on analyst estimates

TempraMed Technologies P&L

In the most recent fiscal year, TempraMed Technologies reported revenue of $1.6M and EBITDA of -$13.1M.

TempraMed Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX

See TempraMed Technologies valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$1.6M	XXX	XXX	XXX
Gross Profit	XXX	$1.0M	XXX	XXX	XXX
Gross Margin	XXX	63%	XXX	XXX	XXX
EBITDA	XXX	-$13.1M	XXX	XXX	XXX
EBITDA Margin	XXX	-793%	XXX	XXX	XXX
EBIT	XXX	-$1.7M	XXX	XXX	XXX
EBIT Margin	XXX	-106%	XXX	XXX	XXX
Net Profit	XXX	-$13.9M	XXX	XXX	XXX
Net Margin	XXX	-845%	XXX	XXX	XXX
Net Debt	XXX	$50K	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for TempraMed Technologies including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, TempraMed Technologies achieved $1.6M in revenue and -$13.1M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$1.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$1.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	62.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$13.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-793.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$1.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-105.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$13.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-844.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$50K	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for TempraMed Technologies

This financial data table provides comprehensive performance metrics for TempraMed Technologies, a company based in Canada. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, TempraMed Technologies reported $1.6M in total revenue.
Fiscal year EBITDA was -$13.1M.
The company maintained a gross profit margin of 62.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was -793.0%.
Net profit margin reached -844.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for TempraMed Technologies. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

TempraMed Technologies Stock Performance

TempraMed Technologies has current market cap of CAD 55.1M (or $40.0M), and EV of CAD 53.6M (or $38.9M).

Market Cap Evolution

TempraMed Technologies Stock Data

As of December 17, 2025, TempraMed Technologies's stock price is CAD 1 (or $1).

See TempraMed Technologies trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$38.9M	$40.0M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

TempraMed Technologies Valuation Multiples

TempraMed Technologies's trades at 23.6x EV/Revenue multiple, and -3.0x EV/EBITDA.

See valuation multiples for TempraMed Technologies and 15K+ public comps

TempraMed Technologies Financial Valuation Multiples

As of December 17, 2025, TempraMed Technologies has market cap of $40.0M and EV of $38.9M.

Equity research analysts estimate TempraMed Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

TempraMed Technologies's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$40.0M	XXX	$40.0M	XXX	XXX	XXX
EV (current)	$38.9M	XXX	$38.9M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	23.6x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-3.0x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-22.4x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-2.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-792.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TempraMed Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

TempraMed Technologies Margins & Growth Rates

TempraMed Technologies's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

TempraMed Technologies's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TempraMed Technologies's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for TempraMed Technologies and other 15K+ public comps

TempraMed Technologies Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-793%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	88%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	168%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial